Potentiation of methamphetamine neurotoxicity by intrastriatal lipopolysaccharide administration

Neurochemistry International

Volumn 56, Issue 2, 2010, Pages 229-244

  Jung, Bae Dong ^a   Shin, Eun Joo ^a   Nguyen, Xuan Khanh Thi ^a   Jin, Chun Hui ^a   Bach, Jae Hyung ^a   Park, Seok Joo ^a   Nah, Seung Yeol ^b   Wie, Myung Bok ^a   Bing, Guoying ^c   Kim, Hyoung Chun ^a  

^a Kangwon National University   (South Korea)

^b Konkuk University   (South Korea)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Apoptosis; Lipopolysaccharide; Methamphetamine; Neuroinflammation; Oxidative stress

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 4 HYDROXYNONENAL; ALPHA SYNUCLEIN; CASPASE 3; CYCLOOXYGENASE 2; DOPAMINE; GAMMA INTERFERON; HISTAMINE; HOMOVANILLIC ACID; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEVODOPA; LIPOPOLYSACCHARIDE; MALONALDEHYDE; METHAMPHETAMINE; NORADRENALIN; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; CORPUS STRIATUM; CYTOPLASM; DOPAMINERGIC SYSTEM; DORSAL RAPHE NUCLEUS; HIPPOCAMPUS; LIPID PEROXIDATION; LOCOMOTION; LOCUS CERULEUS; MALE; MICROGLIA; MONOAMINERGIC SYSTEM; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; ROTAROD TEST; SUBSTANTIA NIGRA;

ALDEHYDES; ANIMALS; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DRUG SYNERGISM; LIPOPOLYSACCHARIDES; MALE; MALONDIALDEHYDE; METHAMPHETAMINE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; PARKINSON DISEASE;

ANIMALIA; MUS;

EID: 77149143852     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2009.10.005     Document Type: Article

References (82)

1. + neurotoxicity in cultures of fetal rat dopaminergic neurons. Exp. Neurol. 1995, 136:44-52.
2. Arai H., Furuya T., Yasuda T., Miura M., Mizuno Y., Mochizuki H. Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1β, and expression of caspase-11 in mice. J. Biol. Chem. 2004, 279:51647-51653.
3. Arimoto T., Bing G. Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. Neurobiol. Dis. 2003, 12:35-45.
4. Arimoto T., Choi D.Y., Lu X., Liu M., Nguyen X.V., Zheng N., Stewart C.A., Kim H.C., Bing G. Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra. Neurobiol. Aging 2007, 28:894-906.
5. Asanuma M., Tsuji T., Miyazaki I., Miyoshi K., Ogawa N. Methamphetamine-induced neurotoxicity in mouse brain is attenuated by ketoprofen, a non-steroidal anti-inflammatory drug. Neurosci. Lett. 2003, 352:13-16.
6. Asanuma M., Miyazaki I., Higashi Y., Tsuji T., Ogawa N. Specific gene expression and possible involvement of inflammation in methamphetamine-induced neurotoxicity. Ann. N.Y. Acad. Sci. 2004, 1025:69-75.
7. Benedetti A., Comporti M., Esterbauer H. Identification of 4-hydroxynonenal as a cytotoxic product originating from the peroxidation of liver microsomal lipids. Biochim. Biophys. Acta 1980, 620:281-296.
8. Bennett M.C., Bishop J.F., Leng Y., Chock P.B., Chase T.N., Mouradian M.M. Degradation of alpha-synuclein by proteasome. J. Biol. Chem. 1999, 274:33855-33858.
9. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 2000, 3:1301-1396.
10. Bing G., Zhang Y., Watanabe Y., McEwen B.S., Stone E.A. Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra. Brain Res. 1994, 668:261-265.
11. Block M.L., Hong J.S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol. 2005, 76:77-98.
12. Campbell I.L., Abraham C.R., Masliah E., Kemper P., Inglis J.D., Oldstone M.B., Mucke L. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:10061-10065.
13. Cannon J.R., Tapias V., Na H.M., Honick A.S., Drolet R.E., Greenamyre J.T. A highly reproducible rotenone model of Parkinson's disease. Neurobiol. Dis. 2009, 34:279-290.
14. Cerruti C., Sheng P., Ladenheim B., Epstein C.J., Cadet J.L. Involvement of oxidative and L-arginine-NO pathways in the neurotoxicity of drugs of abuse in vitro. Clin. Exp. Pharmacol. Physiol. 1995, 22:381-382.
15. Chalmers J.P., Baldessarini R.J., Wurtman R.J. Effects of L-dopa on norepinephrine metabolism in the brain. Proc. Natl. Acad. Sci. U.S.A. 1971, 68:662-666.
16. Chiang C.S., Stalder A., Samimi A., Campbell I.L. Reactive gliosis as a consequence of interleukin-6 expression in the brain: studies in transgenic mice. Dev. Neurosci. 1994, 16:212-221.
17. Choi D.Y., Liu M., Hunter R.L., Cass W.A., Pandya J.D., Sullivan P.G., Shin E.J., Kim H.C., Gash D.M., Bing G. Striatal neuroinflammation promotes Parkinsonism in rats. PLoS One 2009, 4:e5482.
18. Danielson S.R., Andersen J.K. Oxidative and nitrative protein modifications in Parkinson's disease. Free Radic. Biol. Med. 2008, 44:1789-1794.
19. Di Monte D.A., Lavasani M., Manning-Bog A.B. Environmental factors in Parkinson's disease. Neurotoxicology 2002, 23:487-502.
20. Dohm C.P., Kermer P., Bahr M. Aggregopathy in neurodegenerative disease: mechanisms and therapeutic implication. Neurodegenerative Dis. 2008, 5:321-338.
21. Fitzmaurice P.S., Tong J., Yazdanpanah M., Liu P.P., Kalasinsky K.S., Kish S.J. Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine. J. Pharmacol. Exp. Ther. 2006, 319:703-709.
22. Fornai F., Bassi L., Torracca M.T., Scalori V., Corsini G.U. Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice. Eur. J. Pharmacol. 1995, 283:99-102.
23. Fornai F., Lenzi P., Gesi M., Ferrucci M., Lazzeri G., Capobianco L., de Blasi A., Battaglia G., Nicoletti F., Ruggieri S., Paparelli A. Similarities between methamphetamine toxicity and proteasome inhibition. Ann. N.Y. Acad. Sci. 2004, 1025:162-170.
24. Fornai F., Lenzi P., Gesi M., Soldani P., Ferrucci M., Lazzeri G., Capobianco L., Battaglia G., de Blasi A., Nicoletti F., Paparelli A. Methamphetamine produces neuronal inclusions in the nigrostriatal system and PC12 cells. J. Neurochem. 2004, 88:114-123.
25. Gadient R.A., Otten U.H. Interleukin-6 (IL-6) a molecule with both beneficial and destructive potentials. Prog. Neurobiol. 1997, 52:379-390.
26. Giovanni A., Liang L.P., Hasting T.G., Zigmond M.J. Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: impact of methamphetamine. J. Neurochem. 1995, 64:1819-1825.
27. Guilarte T.R. Is methamphetamine abuse a risk factor in Parkinsonism?. Neurotoxicology 2001, 22:725-731.
28. Harvey D.C., Laćan G., Melegan W.P. Regional heterogeneity of dopaminergic deficits in vervet monkey striatum and substantia nigra after methamphetamine exposure. Exp. Brain Res. 2000, 133:349-358.
29. Hirota H., Kiyama H., Kishimoto T., Taga T. Accelerated nerve regeneration in mice by upregulated expression of interleukin (IL) 6 and IL-6 receptor after trauma. J. Exp. Med. 1996, 183:2627-2634.
30. Hodara R., Norris E.H., Giasson B.I., Mishizen-Eberz A.J., Lynch D.R., Lee V.M.Y., Ischiropoulos H. Functional consequences of α-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J. Biol. Chem. 2004, 279:47746-47753.
31. Hunter R.L., Dragicevic N., Seifert K., Choi D.Y., Liu M., Kim H.C., Cass W.A., Sullivan P.G., Bing G. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J. Neurochem. 2007, 100:1375-1386.
32. Hunter R.L., Cheng B., Choi D.Y., Liu M., Liu S., Cass W.A., Bing G. Intrastriatal lipopolysaccharide injection induces Parkinsonism in C57/B6 mice. J. Neurosci. Res. 2009, 87:1913-1921.
33. Jareno E.J., Bosch-Morell F., Fernandez-Delgado R., Donat J., Romero F.J. Serum malondialdehyde in HIV seropositive children. Free Radic. Biol. Med. 1998, 24:503-506.
34. Jin J., Meredith G.E., Chen L., Zhou Y., Xu J., Shie F.-S., Lockhart P.L., Zhang J. Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson's disease. Mol. Brain Res. 2004, 134:119-138.
35. Jin J., Shie F.S., Liu J., Wang Y., Davis J., Schantz A.M., Montine K.S., Montine T.J., Zhang J. Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated α-synuclein. J. Neuroimmunol. 2007, 4:2.
36. Kim H.C., Jhoo W.K., Choi D.Y., Im D.H., Shin E.J., Suh J.H., Floyd R.A., Bing G. Protection of methamphetamine nigrostriatal toxicity by dietary selenium. Brain Res. 1999, 851:76-86.
37. Kim W.G., Mohney R.P., Wilson B., Jeohn G.H., Liu B., Hong J.S. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J. Neurosci. 2000, 20:6309-6316.
38. Kim H.C., Jhoo W.K., Bing G., Shin E.J., Wie M.B., Kim W.K., Ko K.H. Phenidone prevents kainite-induced neurotoxicity via antioxidant mechanisms. Brain Res. 2000, 874:15-23.
39. Kim H.C., Jhoo W.K., Shin E.J., Bing G. Selenium deficiency potentiates methamphetamine-induced nigral neuronal loss; comparison with MPTP model. Brain Res. 2000, 862:247-252.
40. Kim H.C., Shin C.Y., Seo D.O., Jhoo J.H., Jhoo W.K., Kim W.K., Shin E.J., Lee Y.H., Lee P.H., Ko K.H. New morphinan derivates with negligible psychotropic effects attenuate convulsions induced by maximal electroshock in mice. Life Sci. 2003, 72:1883-1895.
41. Kita T., Paku S., Takahashi M., Kubo K., Wagner G.C., Nakashima T. Methamphetamine-induced neurotoxicity in BALB/c, DBA/2N and C57BL/6N mice. Neuropharmacology 1998, 37:1177-1184.
42. Kita T., Wagner G.C., Nakashima T. Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption. J. Pharmacol. 2003, 92:178-195.
43. Koo K.H., Jung B.D., Shin E.J., Khanh N.T.X., Li Z., Park S.J., Chae J.S., Wie M.B., Kim H.C. Methamphetamine potentiates lipopolysaccharide-induced dopaminergic toxicity in mice. Proceedings of the International Convention, vol. 2 2008, P235. The Pharmaceutical Society of Korea.
44. Korsmeyer S.J., Shutter J.R., Veis D.J., Merry D.E., Oltvai Z.N. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin. Cancer Biol. 1993, 4:327-332.
45. Koutsilieri E., Scheller C., Grunblatt E., Nara K., Li J., Riederer P. Free radicals in Parkinson's disease. J. Neurol. 2002, 249:II1-II5.
46. LaVoie M.J., Card J.P., Hastings T.G. Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Exp. Neurol. 2004, 187:47-57.
47. Le Couteur D.G., McLean A.J., Taylor M.C., Woodham B.L., Board P.G. Pesticides and Parkinson's disease. Biomed. Pharmacother. 1999, 53:122-130.
48. Li Z., Choi D.Y., Shin E.J., Hunter R.L., Jin C.H., Wie M.B., Kim M.S., Park S.J., Bing G., Kim H.C. Phenidone protects the nigral dopaminergic neurons from LPS-induced neurotoxicity. Neurosci. Lett. 2008, 445:1-6.
49. Lindner M.D., Plone M.A., Francis J.M., Emerich D.F. Validation of a rodent model of Parkinson's disease: evidence of a therapeutic window for oral Sinemet. Brain Res. Bull. 1996, 39:367-372.
50. Liu B., Hong J.S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther. 2003, 304:1-7.
51. Liu B., Jiang J.W., Wilson B.C., Du L., Yang S.N., Wang J.Y., Wu G.C., Cao X.D., Hong J.S. Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide. J. Pharmacol. Exp. Ther. 2000, 295:125-132.
52. Lorez H. Fluorescence histochemistry indicates damage of striatal dopamine nerve terminals in rats after multiple doses of METH. Life Sci. 1981, 28:911-916.
53. Manning-Bog A.B., McCormack A.L., Li J., Uversky V.N., Fink A.L., Di Monte D.A. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem. 2002, 277:1641-1644.
54. Marshall K.A., Daniel S.E., Cairns N., Jenner P., Halliwell B. Upregulation of the anti-apoptotic protein Bcl-2 may be an early event in neurodegeneration: studies on Parkinson's and incidental Lewy body disease. Biochem. Biophys. Res. Commun. 1997, 240:84-87.
55. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
56. Meredith G.E., Totterdell S., Petroske E., Santa Cruz K., Callison R.C., Lau Y.S. Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Res. 2002, 956:156-165.
57. Miller R.L., James-Kracke M., Sun G.Y., Sun A.Y. Oxidative and inflammatory pathways in Parkinson's disease. Neurochem. Res. 2009, 34:55-65.
58. Nicholas A.P., Buck K., Ferger B. Effects of levodopa on striatal monoamines in mice with levodopa-induced hyperactivity. Neurosci. Lett. 2008, 443:204-208.
59. O'Callaghan J.P., Miller D.B. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 1994, 270:741-751.
60. Oliver C.N., Ahn B.W., Moerman E.J., Goldstein S., Statman E.R. Age-related changes in oxidized proteins. J. Biol. Chem. 1987, 262:5488-5491.
61. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press, San Diego. 2nd ed.
62. Reed J.C. Mechanisms of Bcl-2 family protein function and dysfunction in health and disease. Behring Inst. Mitt. 1996, 97:72-100.
63. Reinheckel T., Ullrich O., Sitte N., Grune T. Differential impairment of 20S and 26S proteasome activities in human hematopoietic K562 cells during oxidative stress. Arch. Biochem. Biophys. 2000, 377:65-68.
64. Sawada H., Kohno R., Kihara T., Izumi Y., Sakka N., Ibi M., Nakanishi M., Nakamizo T., Yamakawa K., Shibasaki H., Yamamoto N., Akaike A., Inden M., Kitamura Y., Taniquchi T., Shimohama S. Proteosome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions. J. Biol. Chem. 2004, 279:10710-10719.
65. Sekine Y., Ouchi Y., Sugihara G., Takei N., Yoshikawa E., Nakamura K., Iwata Y., Tsuchiya K.J., Suda S., Suzuki K., Kawai M., Takebayashi K., Yamamoto S., Matsuzaki H., Ueki T., Mori N., Gold M.S., Cadet J.L. Methamphetamine causes microglial activation in the brains of human abusers. J. Neurosci. 2008, 28:5756-5761.
66. Sonsalla P.K., Jochnowitz N.D., Zeevalk G.D., Oostveen J.A., Hall E.D. Treatment of mice with methamphetamine produces cell loss in the substantia nigra. Brain Res. 1996, 738:172-175.
67. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
68. Sriram K., Miller D.B., O'Callaghan J.P. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-α. J. Neurochem. 2006, 96:706-718.
69. Steffensen S.C., Campbell I.L., Henriksen S.J. Site-specific hippocampal pathophysiology due to cerebral overexpression of interleukin-6 in transgenic mice. Brain Res. 1994, 652:149-153.
70. Tetrud J.W., Langston J.W. MPTP-induced parkinsonism as a model for Parkinson's disease. Acta. Neurol. Scand. Suppl. 1989, 126:35-40.
71. Thomas D.M., Walker P.D., Benjamins J.A., Geddes T.J., Kuhn D.M. Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J. Pharmacol. Exp. Ther. 2004, 311:1-7.
72. Thomas D.M., Dowgiert J., Geddes T.J., Francescutti-Verbeem D., Liu X., Kuhn D.M. Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci. Lett. 2004, 367:349-354.
73. Thomas D.M., Kuhn D.M. MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity. Brain Res. 2005, 1050:190-198.
74. United Nations Office on Drugs and Crime, 2009. World Drug Report 2009. United Nations Publication, New York.
75. Wakabayashi K., Matsumoto K., Takayama K., Yoshimoto M., Takahashi H. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci. Lett. 1997, 239:45-48.
76. Walsh S.L., Wagner G.C. Motor impairments after methamphetamine-induced neurotoxicity in the rat. J. Pharmacol. Exp. Ther. 1992, 263:617-626.
77. Webb J.L., Ravikumar B., Atkins J., Skepper J.N., Rubinsztein D.C. Alpha-Synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 2003, 278:25009-25013.
78. Whitton P.S. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br. J. Pharmacol. 2007, 150:963-976.
79. Wilson J.M., Kalasinsky K.S., Levey A.I., Bergeron C., Reiber G., Anthony R.M., Schmunk G.A., Shannak K., Haycock J.W., Kish S.J. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 1996, 2:699-703.
80. Winson J.M., Levey A.I., Rajput A., Ang L., Guttman M., Shannak K., Niznik H.B., Hornykiewicz O., Pifl C., Kish S.J. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 1996, 47:718-726.
81. Zhang W., Shin E.J., Wang T., Lee P.H., Pang H., Wie M.B., Kim W.K., Kim S.J., Huang W.H., Wang Y., Zhang W., Hong J.S., Kim H.C. 3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro. FASEB J. 2006, 20:2496-2511.
82. Zhong X.H., Haycock J.W., Shannak K., Robitaille Y., Fratkin J., Koeppen A.H., Hornykiewicz O., Kish S.J. Striatal dihydroxy-phenylalanine decarbxylase and tyrosine hydroxylase protein in idiopathic Parkinson's disease and dominantly inherited olivopontocerebellar atrophy. Mov. Disord. 1995, 101:10-17.